Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (Nasdaq: AMRS) serves as a hub for tracking developments at the forefront of sustainable biotechnology. This resource aggregates official updates from the synthetic biology leader currently undergoing strategic restructuring while maintaining its commitment to transforming consumer markets through bioscience innovations.
Investors and industry observers will find comprehensive coverage of financial updates, leadership changes, and operational milestones. The collection includes press releases detailing AMRS's Chapter 11 restructuring progress, R&D advancements through its Lab-to-Market™ platform, and partnerships supporting its shift toward core biotechnology competencies.
Key content focuses on operational restructuring efforts, sustainability initiatives, and technology licensing agreements. Users can monitor updates about the company's consumer brand divestitures, cost optimization strategies, and ongoing supply chain relationships with global manufacturers.
Bookmark this page for streamlined access to verified AMRS communications, including regulatory filings and strategic partnership announcements. Check back regularly for the latest developments as Amyris positions itself for long-term stability in sustainable ingredient markets.
Amyris, Inc. (Nasdaq: AMRS) announced an estimated $56 million in total revenue for Q1 2023, surpassing prior guidance of $50 million. The company is focusing on cost efficiency and liquidity to self-fund its initiatives, with a strategic review underway as part of its 'Fit-to-Win' program. The insourcing production at the technologically advanced Barra Bonita facility has progressed, with the plant now meeting product delivery targets. CEO John Melo expressed confidence in the company's operational efficiency and revenue growth strategy. Amyris expects to secure $335 million in earnouts and milestone payments and aims for an additional $200 million from transactions this year. A detailed update will be provided during the Q1 earnings call on May 9, 2023.
Amyris, Inc. (Nasdaq: AMRS) has completed a strategic transaction with Givaudan SA, securing exclusive worldwide licensing for key cosmetic ingredients including Neossance® Squalane and CleanScreen™. The deal is valued at approximately $500 million, comprising $200 million in upfront cash and up to $150 million in performance-based earnouts. This partnership enhances both companies' positions in sustainable beauty, leveraging Amyris' Lab-to-Market™ technology to produce high-performing bio-fermented ingredients. The collaboration follows a successful history in the commercialization of Bisabolol, further solidifying Amyris' market role in clean, sustainable consumer products.
Amyris, a synthetic biotechnology company, reported Q4 2022 Consumer revenue of $52.8 million, marking a 64% increase year-over-year, contributing to full-year Consumer revenue of $176.9 million, up 92%. Core revenue reached $75.8 million in Q4, a 17% increase, with full-year Core revenue at $269.8 million, growing 44%. The company improved cash usage for operating and investing activities sequentially each quarter, reducing cash use from $200 million in Q1 to $97 million in Q4. Significant capital financing of $200 million was secured, and strategic partnerships were expanded. Despite challenges in Technology Access revenue and increased cash operating expenses, Amyris aims for profitability and self-sufficiency by end of 2023.
Amyris, Inc. (Nasdaq: AMRS) announced it will release its financial results for the fourth quarter and full year ended December 31, 2022, on March 15, 2023, post-market close. CEO John Melo and CFO Han Kieftenbeld will lead a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide a business update. Participants can access the call via the company's Investor Relations website or by phone at (844) 850-0551.
Amyris focuses on sustainable health and beauty products and holds a proprietary Lab-to-Market™ technology, serving over 300 million consumers through more than 20,000 products.
